INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics
- Acronyms INTERVAL
- 05 Nov 2019 Planned End Date changed from 31 Aug 2020 to 6 Jan 2020.
- 05 Nov 2019 Planned primary completion date changed from 31 Aug 2020 to 6 Jan 2020.
- 05 Nov 2019 Status changed from recruiting to active, no longer recruiting.